| 
Onno van de Stolpe - Chief Executive Officer
Mr. Van de Stolpe founded Galapagos in 1999 while he was Managing
Director Genomics at Introgene (now Crucell). Prior to joining Introgene
in 1998, he was Managing Director of Molecular Probes Europe. He
established this European headquarters after joining Molecular Probes
in the US. Previously, he worked for the Netherlands Foreign Investment
Agency in California, where he was responsible for recruiting biotech
and medical device companies to locate in the Netherlands. Mr. Van
de Stolpe started his career as Manager Business Development at
MOGEN in Leiden. He received a MSc degree from the Agricultural
University in Wageningen.
Guillaume
Jetten - Chief Financial Officer
Prior to joining Galapagos in July 2009, Mr. Jetten was CFO of SDU
Holding BV, a privately owned company specialized in publishing
and identification documents, where he played a key role in the
Company’s transition from a state owned firm since joining
in 2007. Previously, he was CFO of Wolters Kluwer Health in Chicago,
where he drove initiatives to improve global financial and operating
processes and create synergies of scale. He also served as Vice
President Group Accounting at Wolters Kluwer NV and held positions
with increasing level of responsibilities at Merck, Sharpe &
Dohme BV. Mr. Jetten holds a masters degree in economics from the
University of Maastricht and is a Certified Registered Accountant.
Graham
Dixon, PhD - Senior Vice President Drug Discovery
Dr. Dixon joined Galapagos in 2004. Prior to Galapagos, Dr. Dixon
was CSO of Entomed in France. From 2002 to 2003, he was CSO at F2G
in the UK. From 1994-2002, Dr. Dixon had various research &
development management positions at Zeneca and AstraZeneca. He started
his professional career with Dow and later DowElanco. He has a PhD
in Biochemistry from the University of Swansea in the UK.
Andre
Hoekema, PhD - Senior Vice President Corporate Development
Dr. Hoekema joined Galapagos in March 2005 from Invitrogen Corporation,
where he was Managing Director of Corporate Development Europe.
He brings 20 years of biotech experience from positions at Molecular
Probes Europe (Managing Director), Crucell (Director of Business
Development), DSM Life Sciences and MOGEN (Research and Project
Management) and Genentech, Inc (R&D). Dr. Hoekema has a PhD
degree from Leiden University and is the inventor of over 20 series
of patent applications, resulting in 15 patents issued in the US.
Chris
Newton, PhD - Senior Vice President Galapagos Services
Dr. Newton joined Galapagos in 2005 as SVP BioFocus. Between 2000
and 2005, he was a founding scientist and CSO and Board Director
at Argenta Discovery Ltd. From 1979 to 2000, he held a variety of
senior management positions in both research and development in
the Rhone-Poulenc group of companies, working on a variety of projects,
some of which reached clinical trials. Dr. Newton holds a degree
in Natural Sciences from the University of Cambridge and is Emeleus
chemistry prize holder of that university. He earned his PhD at
the University of Sheffield in 1979, for which he was awarded the
Turner Prize. Dr. Newton has been appointed to visiting academic
fellowships and professorships associated with the University of
Warwick (1994-1998) and the University of Essex (1995-1999) during
his industrial career.
Piet
Wigerinck, PhD – Senior Vice President Development
Dr.
Piet Wigerinck joined Galapagos in April 2008 from Tibotec (a subsidiary
of Johnson & Johnson) where he was VP Drug Discovery, Early
Development and CM&C, and a member of the Management Board.
He started his professional career as a medicinal chemist at Janssen
Research Foundation in 1992. He then joined Tibotec in 1998, where,
under his leadership, TMC114 (PrezistaTM) was selected and moved
forward into clinical trials. Dr. Wigerinck also played a key role
in Tibotec’s expansion into novel diseases such as Hepatitis
C and advanced several compounds into Phase I and Phase II clinical
trials. He brings over 15 years of research and development experience
from both big pharma and biotech to Galapagos. Piet Wigerinck holds
a PhD from the K.U. Leuven and is inventor on more than 25 patent
applications.
|
